Roche reported positive Phase 3 data for its oral selective estrogen receptor degrader (SERD) giredestrant in the adjuvant setting for ER-positive, HER2-negative early breast cancer. At a preplanned interim analysis, the drug extended invasive disease–free survival versus standard endocrine therapy, meeting the trial’s primary endpoint and showing a favorable trend on overall survival, Roche and reporting outlets said. The result marks a potential expansion of SERDs from advanced to earlier-stage disease. Roche disclosed the findings in corporate statements and press coverage; analysts noted an approval in the adjuvant setting could broaden giredestrant’s market and position the drug competitively against oral SERDs under development by AstraZeneca, Lilly and others. The data were presented alongside commentary about trial design differences with competitor programs and longer-term survival readouts that remain pending.